Originals

International Journal of Clinical and Laboratory Research

, Volume 23, Issue 1, pp 34-37

Soluble interleukin-2 receptor in hairy-cell leukemia: a reliable marker of disease

  • Achille AmbrosettiAffiliated withDepartment of Hematology, Verona University School of Medicine
  • , Gianpaolo NadaliAffiliated withDepartment of Hematology, Verona University School of Medicine
  • , Fabrizio VinanteAffiliated withDepartment of Hematology, Verona University School of Medicine
  • , Maria Maddalena RicettiAffiliated withDepartment of Hematology, Verona University School of Medicine
  • , Giuseppe TodeschiniAffiliated withDepartment of Hematology, Verona University School of Medicine
  • , Lorella MorosatoAffiliated withDepartment of Hematology, Verona University School of Medicine
  • , Donata de SabataAffiliated withDepartment of Hematology, Verona University School of Medicine
  • , Ivo Andrea Bergamo AndreisAffiliated withDepartment of Radiology, Verona University School of Medicine
  • , Marco ChilosiAffiliated withDepartment of Pathology, Verona University School of Medicine
    • , Gianpietro SemenzatoAffiliated withDepartment of Clinical Medicine, First Medical Clinic, Padua University School of Medicine
    • , Giovanni PizzoloAffiliated withDepartment of Hematology, Verona University School of Medicine

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary

The CD25 molecule, which corresponds to the p55 α chain of the interleukin-2 receptors, is strongly expressed by neoplastic cells in hairy-cell leukemia and is released in large amounts in the soluble form which is detectable in serum. In order to assess the reliability of the soluble interleukin-2 receptor as a disease marker in the management of patients with hairy-cell leukemia, we investigated serum levels in 35 untreated patients and in 2 patients with the hairy-cell leukemia variant. In 21 of 35 patients soluble receptor levels were also monitored during and after recombinant interferon-α therapy. Clinical and hematological parameters were also assessed. Soluble interleukin-2 receptor levels were extremely high at the time of diagnosis in patients with typical hairy-cell leukemia [32,722±27,001 vs. 331±145 units/ml in controls (mean±SD)], but not in patients with the leukemia variant. A progressive decrease in soluble interleukin-2 receptor levels paralleled the clinical response to treatment, although normal values were never detected, even in patients who achieved an apparent complete remission. After recombinant interferon-α discontinuation, disease recurrence was accompanied by a progressive increase to pre-treatment soluble receptor levels. Overall, a close correlation was found between soluble interleukin-2 receptor values and total tumor burden (r=0.84,P<0.001). On the basis of these data, soluble interleukin-2 receptor should be regarded as a key marker in the management of patients with hairy-cell leukemia.

Key words

Hairy-cell leukemia Soluble interleukin-2 receptor Minimal residual disease